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10 Neural tube defects (NTDs) are common birth defects of complex etiology. Though family- and population-based
studies have confirmed a genetic component, the responsible genes for NTDs are still largely unknown. Based on the
hypothesis that folic acid prevents NTDs by stimulating methylation reactions, epigenetic factors, such as DNA
methylation, are predicted to be involved in NTDs. Homeobox (HOX) genes play a role in spinal cord development and
are tightly regulated in a spatiotemporal and collinear manner, partly by epigenetic modifications. We have quantified
15 DNA methylation for the different HOX genes by subtracting values from a genome-wide methylation analysis using
leukocyte DNA from 10 myelomeningocele (MMC) patients and 6 healthy controls. From the 1575 CpGs profiled for the
4 HOX clusters, 26 CpGs were differentially methylated (P-value < 0.05; b-difference > 0.05) between MMC patients and
controls. Seventy-seven percent of these CpGs were located in the HOXA and HOXB clusters, with the most profound
difference for 3 CpGs within the HOXB7 gene body. A validation case-control study including 83 MMC patients and 30
20 unrelated healthy controls confirmed a significant association between MMC and HOXB7 hypomethylation (-14.4%; 95%
CI: 11.9–16.9%; P-value < 0.0001) independent of the MTFHR 667C>T genotype. Significant HOXB7 hypomethylation
was also present in 12 unaffected siblings, each related to a MMC patient, suggestive of an epigenetic change induced
by the mother. The inclusion of a neural tube formation model using zebrafish showed that Hoxb7a overexpression but
not depletion resulted in deformed body axes with dysmorphic neural tube formation. Our results implicate HOXB7
25 hypomethylation as risk factor for NTDs and highlight the importance for future genome-wide DNA methylation
analysesQ2 without preselecting candidate pathways.
Introduction
Neural tube defects (NTDs), affecting 0.5–2 per 1000 preg-
nancies, arise as a failure of the neural tube to close in the cranial
30 (anencephaly) or the caudal (myelomeningocele) region. 1-3 The
nature and severity of NTDs is determined by the stage and axial
level at which closure fails. Cranial NTDs are mostly not com-
patible with life, while caudal NTDs give rise to lifelong disabil-
ities. Although more than 250 genes are known to cause NTDs
35 in mice 4,5 and many candidate genes have been studied in
patient cohorts, the molecular basis underlying NTDs still
remains largely unknown. Folic acid reduced the incidence of
NTDs by 50–75%. 6 However, in most NTD-affected pregnan-
cies maternal folic acid levels are within the normal range 7 and,
40 despite optimal supplementation, a significant proportion of
NTDs are unresponsive to folic acid. 6,8 This would suggest the
existence of folic acid resistance in mothers at risk for NTD-
affected pregnancies, but this hypothesis is not supported by
genetic and/or environmental risk factors. Folic acid is central to
45the one-carbon metabolism that produces pyrimidines and
purines for DNA synthesis and for the generation of S-adenosyL-
methionine, which is a methyl donor for DNA, RNA, and pro-
tein methylation. The only well-characterized genetic risk factor
for NTDs is the 677C>T variant in the 5,10-methylene tetrahy-
50drofolate reductase gene (MTHFR), causing thermolability of the
enzyme and predicted to divert the available methyl groups from
the DNA methylation toward the DNA synthesis pathway. 6
Interestingly, the MTHFR 677C>T variant is associated with
global DNA hypomethylation in both controls and NTDs,6,9
55and this seems to be more pronounced under low folic acid con-
ditions. 10 Most DNA methylation studies in patients with
NTDs were performed independently of the presence of the
MTHFR 677C>T variant. Findings of global DNA and LINE-1
hypomethylation were found in fetal neural tissue DNA from
60NTD patients, suggesting that disruption of genomic stability
may lead to abnormal neural tube closure. 11,12
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Table 1 Background information of MMC patients included in the HumanMethylation450 BeadChip and Sequenom EpiTYPER
MMC
patient Sibling
MMC
patient
Type
MMC Hy/VP ACM Scoliosis ADL UI Ethnicity
Maternal age
(years) at birth of
MMC patient
MTHFR
677C>T Gender
MTHFR
677C>T Gender
MMC patient
versus sibling
age (months)
1*C S yes 1 yes 2 yes Belgian 36 CC F
2*C LS yes 2 yes 3 yes Belgian 29 CT F
3*C LS yes 2 yes 3 yes Moroccan 32 CT M
4*C LS yes 1 yes 3 yes Indonesian 26 CC F
5*C LS yes 2 no 2 yes Belgian CC M CC F ¡18
6*C LS yes 2 yes 3 yes Belgian 27 CC F
7*C LS yes 1 yes 3 yes Belgian CC M
8*C S yes 2 no 1 yes Belgian 27 CC F
9* S no 0 no 1 yes Belgian TT M
10* LS yes 2 no 2 yes Belgian 25 CC M
11C LS yes 2 yes 3 yes Belgian 27 CC M
12C LS yes 2 yes 3 yes Turkish 28 CC F
13C S yes 0 no 1 yes Belgian 33 CT M
14C LS yes 2 yes 3 yes Belgian CC F
15C LS yes 2 yes 3 yes Turkish 20 CT F
16C S yes 2 yes 3 yes Belgian TT M
17C LS yes 2 yes 3 yes Belgian 25 CT F
18C S yes 2 yes 2 yes Belgian 28 CC M
19C LS yes 2 no 1 yes Belgian 36 CT M
20C LS yes 2 yes 1 yes Belgian CT M
21C LS yes 2 yes 3 yes Belgian 36 CT F
22C TL & LS yes 2 yes 3 yes Belgian 23 CC M
23C S no 0 yes 1 yes Belgian 30 CT M
24C LS yes 2 yes 2 yes Belgian 25 CT F
25C LS yes 2 no 2 yes Belgian 34 CC F
26C LS no 0 no 1 yes Belgian CC F
27C LS yes 2 yes 3 yes Belgian CT M CC F ¡20
28C LS yes 2 yes 3 yes Moroccan CT F
29C LS yes 2 yes 3 yes Belgian 31 CC M CC M ¡19
30C LS yes 0 no 1 yes Mongolian CC F
31C LS no 0 no 1 no Belgian 20 TT M CC M ¡20
32C LS yes 2 no 1 yes Belgian 22 CC M
33C LS yes 2 yes 2 yes Belgian 28 CT M
34C LS yes 2 yes 3 yes Belgian CT F
35C S yes 2 no 1 yes Belgian 33 CT M
36C LS yes 2 no 3 yes Belgian 27 CC M
37C LS yes NA yes 2 yes Belgian 26 CT F
38C LS yes 2 yes 2 yes Belgian CT F
39C LS yes 2 yes 3 yes Belgian 28 CT F
40C LS yes 2 no 1 yes Belgian 32 CC M
41C LS no NA no 3 yes Belgian 36 CC M CT M ¡26
42C L yes 2 yes 3 yes Ukrainian 20 CC F
43C LS yes 2 no 1 yes Belgian 25 CC F TT M 20
44C LS yes 2 yes 3 yes Belgian CC M
45C LS yes 2 yes 3 yes Belgian 29 CT F
46C LS yes 2 yes 3 yes Belgian CC F
47C S yes 2 no 1 yes Moroccan 31 CT F
48C LS yes 2 yes 2 yes Belgian 27 CT F
49C S yes 2 yes 3 yes Belgian 34 CC F
50C S no NA no 1 yes Belgian 36 CT F CC F 17
51C LS yes 2 no 3 yes Belgian 30 CC F
52C LS yes 2 no 1 yes Moroccan 24 CC F
53C S yes 2 no 1 yes Belgian 28 CC F
54C S no NA no 1 yes Belgian CT F
55C LS yes 2 no 2 yes Bosnian 31 CT F CC M 53
56C S no 0 no 1 yes Belgian 30 CC F
(Continued on next page)
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The methylation hypothesis suggests that folic acid prevents
NTDs by enhancing cellular methylation reactions. It is known
that a tight regulation of genome-wide erasure of epigenetic foot-
65 prints with resetting of the methylation signature is critical for
normal embryogenesis and, therefore, it is believed that DNA
methylation changes and genomic instability may disturb neural
tube folding. 13 Immediately post fertilization, rapid de-methyla-
tion takes place, followed by re-methylation in the blastocyst and
70 early embryo. It is expected that changes in cytosine methylation
are not randomly distributed in the genome but are preferentially
located at loci that are more sensitive to these processes. Methyl-
ome analysis during early embryonic differentiation showed
changes in the methylation patterns for developmental regulatory
75 genes, such as Homeobox (HOX) genes. 14 The HOX gene clus-
ters comprise a family of genes assembled in 4 clusters (HOX A,
B, C, and D, located on chromosomes 7, 17, 12, and 2, respec-
tively). HOX genes encode highly conserved transcription factors
expressed in the brain and spinal cord that play a central role in
80establishing the anterior-posterior body axis during embryogene-
sis (Fig. S1). 15,16 Their expression is tightly regulated in a spatio-
temporal and collinear manner, partly by chromatin structure
and epigenetic modifications. 17-19 Though genetic studies could
not show an association between variants in HOX genes and
85NTDs,15 DNA methylation studies for the HOX cluster genes
have not yet been performed.
We hypothesize that children born from mothers with folic
acid resistance and a disturbed methylation cycle can present
with an abnormal DNA methylation profile for HOX genes,
90resulting in increased risk for abnormal embryonic develop-
ment and NTDs. Therefore, the aim of this study was to
investigate DNA methylation of HOX genes as mediator of
NTD risk using data extracted from a genome-wide DNA
methylation analysis study performed for 10 patients with
95lumbosacral MMC and 6 healthy unrelated controls. A valida-
tion study was performed to quantify locus-specific methyla-
tion differences in larger cohorts. The functional
Table 1 Background information of MMC patients included in the HumanMethylation450 BeadChip and Sequenom EpiTYPER (Continued)
MMC
patient Sibling
MMC
patient
Type
MMC Hy/VP ACM Scoliosis ADL UI Ethnicity
Maternal age
(years) at birth of
MMC patient
MTHFR
677C>T Gender
MTHFR
677C>T Gender
MMC patient
versus sibling
age (months)
57C LS yes 2 no 1 yes Belgian 24 CC F
58C S no 2 no yes Moroccan 26 CC F
59C LS yes 2 yes 3 yes Belgian 27 CC F
60C LS yes 2 no 1 yes Turkish 35 CT F CC F ¡101
61C LS yes 2 yes 3 yes Belgian CT F
62C LS yes 2 no 1 yes Turkish 29 CT F
63C LS yes 2 yes 3 yes Belgian 35 CT F
64C L & CP yes 2 no 2 yes Belgian 40 CT F CT F ¡27
65C LS yes 2 yes 2 yes Belgian CT F
66C LS yes 2 yes 2 yes Belgian 24 CT F
67C LS yes 2 yes 2 yes Belgian CT F
68C S yes 2 no 1 no Belgian CT M
69C LS yes 2 yes 3 yes Belgian 24 CT M
70C LS yes 2 yes 3 yes Belgian 29 CC M
71C LS yes 2 yes 3 yes Belgian 33 CC F
72C LS yes 2 yes 2 yes Belgian 29 CC M
73C LS yes 2 yes 3 yes Belgian 29 CT F CT F ¡24
74C LS yes 2 yes 2 yes Belgian CT M
75C LS yes 2 no 1 yes Belgian CC F
76C LS yes 2 yes 2 yes Belgian 31 CT F
77C LS yes 2 yes 3 yes Belgian 26 CC M
78C LS yes 2 yes 3 yes Belgian 30 CT M
79C S no 0 no 1 yes Belgian CT M
80C LS yes 2 no 1 yes Belgian 30 CC F
81C LS yes NA no 2 yes Turkish CT M
82C TL yes 2 yes 3 yes Belgian TT F
83C TL yes 2 yes 1 yes Belgian 24 TT F
84C TL yes 1 yes 3 yes Belgian 37 CC F
85C TL yes 2 no 1 no Belgian TT F
*Inclusion in HumanMethylation 450K BeadChip (10 MMC patients) and CSequenom EpiTYPER (83 MMC patients); MMC: myelomeningocele; M: male; F:
female; S: Sacral; LS: Lumbosacral; TL: Thoracolumbal; CP: Cheilopalatoschisis; Hy/VP: presence of hydrocephaly and ventriculoperitoneal drain; ACM: Arnold
Chiari Malformation: 1 D type 1, 2 D type 2; NA: Not Available; ADL: Activities of daily life: 1 D ambulatory, 2 D household ambulatory with wheelchair for
longer distances, 3 D wheelchair dependent; UI: urinary incontinence; MTHFR 677C>T genotype (CC/CT/TT) in 85 MMC patients: 47% CC - 53% CT/TT vs.
40% CC - 60% CT/TT in 30 healthy unrelated controls (P-value D ns).
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characterization of the candidate HOX gene was finally ana-
lyzed using a zebrafish model of neural tube formation.
100 Results
DNA methylation analysis of the different HOX genes
in MMC case-control study
Methylation values for all CpGs located within the 4 HOX
clusters were extracted from data obtained from a 450K
105 array-based genome-wide methylation analysis, using leuko-
cyte DNA from 10 MMC cases and 6 unrelated age- and
gender-matched healthy controls. Detailed clinical characteris-
tics of these MMC patients are reported in Table 1. Pie
charts were made to show the equal distribution of the fil-
110 tered CpG probes (n D 967) based on: i) location within the
4 different HOX clusters; ii) location with respect to gene
transcripts; and iii) location with respect to the CpG island
(Fig. S2). From the 967 filtered CpGs profiled on the 450K
array (Table S1), only 26 CpGs were found to be differen-
115 tially methylated between MMC patients and controls
(Table 2, Fig. S2). Interestingly, 25 of these 26 CpGs were
hypomethylated for the MMC patients and 20 of the 26
CpGs were located within the HOXA or HOXB clusters.
Only for the HOXB7 gene, 3 different CpG probes
120(cg11041817, cg22622477, and cg07547765) were signifi-
cantly hypomethylated in MMC patients (b-differences of
¡0.29, ¡0.16, and ¡0.26, respectively, with all P-values of
0.007). These 3 probes are located within a single CpG
island at chr17:46,685,244–46,685,449, within the HOXB7
125gene body (Fig. 1A).
HOXB7 methylation analysis in MMC case-control study
A validation study using larger cohorts (83 MMC patients
described in Table 1) was performed with the Sequenom Epi-
TYPER technology to quantify methylation of the above selected
130CpG islands located in the HOXB7 gene body. A Sequenom
amplicon was developed that covers 26 CpGs (Fig. 1A), includ-
ing the 3 significant CpGs detected in the 450K array. Within
this amplicon, the EpiTYPER detected 10 analytical CpG units
for which CpG6 is similar to cg07547765. DNA methylation
135values for the amplicon for 83 MMC patients and 30 unrelated
healthy controls were normally distributed (Shapiro-Wilk test,
P>0.05). A significant HOXB7 hypomethylation (P-value <
0.0001) was detected for MMC patients versus controls with
mean methylation values of 41% (95% CI: 38–45%) vs. 56%
140(95% CI: 50–61%), respectively (Fig. 1B). The mean level of
methylation for each CpG unit within the amplicon was also sig-
nificantly different between MMC patients and controls (Fig. 1C
and Table S2). To exclude an effect of changes in methylation
Table 2Methylation of the HOX genes using the HumanMethylation450 BeadChip and analysis
Ctrls (n D 6) MMC (n D 10)
Cluster Gene Chr Illumina ID
P-value
<0.05
b-diff
>0.05 Mean SD Mean SD
A: Chr.7p14 HOXA2 7 cg06055873 0.016 ¡0.06 0.32 0.03 0.26 0.04
HOXA2 7 cg19432993 0.031 ¡0.12 0.69 0.05 0.57 0.12
HOXA2 7 cg06166490 0.016 ¡0.12 0.70 0.06 0.58 0.11
HOXA2 7 cg04027736 0.022 ¡0.11 0.61 0.06 0.50 0.11
HOXA2 7 cg00445443 0.042 ¡0.10 0.41 0.08 0.31 0.11
7 cg15037137 0.007 ¡0.05 0.85 0.02 0.80 0.07
HOXA4 7 cg25952581 0.042 ¡0.09 0.45 0.06 0.37 0.11
HOXA4 7 cg17591595 0.042 ¡0.08 0.73 0.05 0.65 0.09
HOXA11 7 cg24709033 0.011 ¡0.06 0.27 0.03 0.21 0.04
B: Chr.17q21 HOXB5 17 cg01405107 0.042 0.09 0.49 0.05 0.58 0.08
HOXB6 17 cg09983216 0.016 ¡0.13 0.55 0.08 0.42 0.10
HOXB7 17 cg11041817 0.007 ¡0.29 0.70 0.08 0.41 0.20
HOXB7 17 cg22622477 0.007 ¡0.16 0.36 0.06 0.20 0.09
HOXB7 17 cg07547765 0.007 ¡0.26 0.71 0.10 0.44 0.18
17 cg19051015 0.022 ¡0.09 0.72 0.05 0.63 0.07
HOXB9 17 cg15117739 0.007 ¡0.10 0.68 0.04 0.57 0.07
HOXB9 17 cg12057127 0.042 ¡0.06 0.72 0.01 0.67 0.07
17 cg20454400 0.031 ¡0.06 0.37 0.04 0.31 0.05
17 cg16654603 0.011 ¡0.09 0.67 0.02 0.58 0.08
17 cg02052915 0.016 ¡0.05 0.36 0.03 0.31 0.04
C: Chr.12q13 12 cg08299265 0.016 ¡0.06 0.39 0.04 0.33 0.03
12 cg26643142 0.031 ¡0.06 0.35 0.03 0.30 0.05
HOXC4 12 cg18473521 0.011 ¡0.12 0.43 0.08 0.31 0.07
D: Chr.2q31 HOXD9 2 cg04730882 0.005 ¡0.07 0.35 0.03 0.28 0.05
2 cg07783843 0.011 ¡0.06 0.24 0.02 0.18 0.04
2 cg05525812 0.007 ¡0.07 0.25 0.02 0.18 0.05
Nucleotide positions in accord to NCBI build 37/hg19. Selection is performed along both b-value > 0.05 difference and P-value < 0.05; calculated with Wil-
coxon Rank-Sum test. The 3 probes in bold are located within the same CpG island at Chr17:46,685,244–46,685,449 within the HOXB7 gene body. This
region was selected for the validation study using Sequenom EpiTYPER. b-diff: b-difference; Chr: chromosome; Ctrls: controls; MMC: myelomeningocele.
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due to differences in ethnicity, the HOXB7 methylation pattern
145 between 70 Belgian MMC patients was compared to 10 non-
Caucasian MMC patients without significant differences
(Fig. S3).
As findings of global DNA hypomethylation and LINE-1
hypomethylation suggest that disruption of genomic stability
150 may disrupt neural tube closure and the MTHFR 677C>T vari-
ant is associated with global DNA hypomethylation, we
determined the MTHFR 677C>T vari-
ant for MMC patients and healthy con-
trols (Table 1). Interestingly, an intrinsic
155defect in the folic acid pathway related
to MTHFR activity seems not to be
involved, as no association was found
between MTHFR 677 CC versus
CTCTT carriers and HOXB7 methyla-
160tion (Fig. 1D).
HOXB7 methylation analysis in
unaffected siblings of MMC patients
For 12 out of 83 MMC patients,
DNA was also collected from their
165healthy siblings (Table 1). Remarkably,
the mean methylation level of the
HOXB7 amplicon was not different
between MMC patients and their unaf-
fected siblings with values of 37% (95%
170CI: 33–40%) vs. 40% (95% CI:
37–42%) (Fig. 2A). Multiple T-testing
for each CpG within the HOXB7 ampli-
con also showed no significant differen-
ces between patients and healthy siblings
175(Fig. 2B and Table S2).
HOXB7 methylation versus
expression
Since leukocyte RNA was not col-
lected for our cohorts, we used the
180MENT database to estimate a correla-
tion between HOXB7 methylation and
gene expression. The 2 CpGs
(cg09357097 and cg06493080) located
in the HOXB7 promoter (Fig. 1A)
185showed no correlation with gene expres-
sion in normal brain and blood tissues.
However, there is evidence that lower
HOXB7 methylation values in brain
tightly regulate higher and stable gene
190expression levels compared to the higher
methylation levels in blood that are asso-
ciated with variable gene expression
(Fig. S4). Interestingly, cg06493080
showed strong negative correlation with
195gene expression in different cancer tis-
sues, especially for brain (correlation
¡0.15; P-value D 0.008).
Hoxb7a overexpression and depletion in zebrafish
Functional genetics was performed in zebrafish to study altera-
200tions in Hoxb7a expression during embryogenesis and neural
tube formation. The regulation of the HOX clusters is highly
conserved between humans and zebrafish (Fig. S1). Hoxb7a has
an anterior expression limit adjacent to the somite 3–4 boundary
at the 20 somite stage. 20 We analyzed embryos with Hoxb7a
Figure 1. HOXB7 methylation studies by Sequenom EpiTYPER in MMC patients. A: Localization
of the studied amplicon (Chr17:46,685,144–46,685,550) within HOXB7 Exon 2. The amplicon covers
26 single CpGs and our assay provides data 10 analytical CpG units. Nucleotide positions accord to
the NCBI build 37/hg19. The CpG units studied by 450K Array (cg11041817, cg22622477 and
cg07547765) and the in silico analysis (cg06493080, cg09357097) are also indicated. B: Boxplot repre-
senting the methylation pattern of MMC patients and controls with box D 25th and 75th percentiles;
bars D min and max values. The mean methylation level of each group is shown below the plot. C:
Methylation pattern for each CpG unit within the amplicon. Wilcoxon Rank-Sum test was performed.
D: Boxplot representing the methylation pattern of MMC patients and controls divided according to
MTHFR 677C>T genotype with box D 25th and 75th percentiles; bars D min and max values. The
mean methylation level of each group is shown below the plot.
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205 depletion and overexpression using microinjection of a splice
morpholino (MO) and synthetic Hoxb7a mRNA, respectively.
MO-induced Hoxb7a depletion resulted in hypopigmentation
and developmental delay with dysmorphy in 83–94% of the
embryos at 24 hours post fertilization (hpf) (Fig. S5). However,
210 pax2a staining to visualize neural tube formation at 24 hpf was
not different between Hoxb7a- or control-MO injected embryos,
even for the severely affected Hoxb7a depleted embryos
(Fig. S5). Embryos injected with different concentrations of
Hoxb7a mRNA also presented with severe to mild malforma-
215 tions in about 48–71% of the embryos at 24 hpf (Fig. 3B).
These embryos had shorter anterior/posterior axes as well as
crooked or bent tails (Fig. 3A). Interestingly, pax2a staining
after overexpression of Hoxb7a for different concentrations
showed a neural tube was that was absent or completely disorga-
220 nized (Fig. 3C).
Discussion
As HOX genes play key roles in neural tube closure and many
studies have shown that folic acid prevents NTDs by stimulating
cellular methylation reactions, we extracted methylation data for
225 the different HOX genes from a genome-wide DNA methylation
analysis performed for 10 MMC patients and 6 unrelated healthy
controls. Interestingly, 25 of the 26 CpGs were hypomethylated
for the MMC patients with the HOXB7 gene body as most sig-
nificant locus. Interestingly, HOXB7 hypomethylation was not
230only confirmed in a larger MMC cohort but was also detected in
12 healthy siblings each related to a MMC patient. These results
are suggestive of a maternal effect that contributes to HOXB7
hypomethylation. Additional healthy siblings must be recruited
but gender, age, MTHFR 677C>T genotype, or whether MMC
235is the firstborn, did not seem to be predictive risk factors for
NTDs, based on data for these sibling pairs (Table 1). HOXB7
hypomethylation by itself is not likely to be causative for NTDs
but rather be part of a complex combination of environmental
and (epi)genetic risk factors. We found no association between
240MTHFR CC vs. CTCTT carriers and HOXB7 methylation, sug-
gesting that an intrinsic defect in the folic acid pathway related to
MTHFR activity is not involved. Though we made no measure-
ments of maternal folic acid levels or uptake, it is known that
folic acid levels in most affected pregnancies are within the nor-
245mal range, 7 and, despite optimal supplementation, a significant
proportion of NTDs are unresponsive to folic acid. 6,8 We there-
fore hypothesize that these mothers have folic acid resistance
leading to a disturbed methylation cycle with alterations in DNA
methylation and an increased risk for abnormal embryonic devel-
250opment. Additional studies must be undertaken to study the
association between maternal folic acid intake and HOXB7meth-
ylation in DNA from the mother and her offspring.
HOX genes encode for evolutionary highly conserved tran-
scription factors expressed in the central nervous system
255(Fig. S1). They are tightly regulated in a spatiotemporal and col-
linear manner 17-19, patterning the embryo along the rostro-cau-
dal axis. The HOXA and HOXB clusters have a closer
phylogenetic relationship and hence share more functionality
than with either the HOXC or HOXD cluster. 21 Their coopera-
260tive functioning is necessary for the generation of the cranial neu-
ral crest and craniofacial diversity. 22-24 The spinal cord is a
caudal structure, but the neural cells from which it derives ini-
tially express rostral, forebrain-like characteristics. The caudal
character emerges soon after neural induction, through different
265extrinsic signals. 25,26 According to our study, differential HOX
gene methylation in MMC patients occurs in both anterior and
posterior HOX genes. Moreover, failure in establishing correct
HOX gene methylation in the HOXA and HOXB clusters may
result in disturbances in neural cell identity that ultimately leads
270to neural malformations. HOX gene clusters are evolutionary
highly conserved between human and zebrafish and a neural tube
formation zebrafish model was previously used to study
VANGL1. 27 HOX7 has 2 paralog members in humans and only
one in zebrafish (Fig. S1) but the zebrafish Hoxb7a gene shares
27560% homology with the human HOXB7 sequence. As HOXB7
hypomethylation is suggestive for HOXB7 overexpression,
Hoxb7a overexpression experiments were performed in zebrafish.
Overexpression of Hoxb7a in zebrafish resulted in developmental
abnormalities and pax2a staining showed abnormal neural tube
280formation in about 60% of the embryos.
In the present study, we were not able to use patient DNA
samples from brain or spinal cord tissue. Concordant DNA
Figure 2. HOXB7 methylation studies by Sequenom EpiTYPER in
pairs of unaffected siblings vs. MMC patients. A: Boxplot representing
the methylation pattern of affected siblings and unaffected siblings with
box D 25th and 75th percentiles; bars D min and max values. The mean
methylation level of each group is shown below the plot. B: Methylation
pattern for each CpG unit within the amplicon. Wilcoxon Rank-Sum test
was performed.
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methylation profiles in brain and blood samples from the same
individuals suggest that blood might hold promise as surrogate
285 for brain tissue to detect DNA methylation. 28-30 Genome-wide
methylation arrays revealed similar methylation patterns for the
HOX genes in breast cancers and white blood cells, which sug-
gests that methylation is more likely to be a normal
developmental and tissue-specific process that does not directly
290relate to the malignant mechanism. 31 Interestingly, functional in
silico analysis using the MENT database showed no correlation
with gene expression in normal brain and blood tissues for the
methylation of 2 HOXB7 promoter CpGs but there is evidence
that lower HOXB7 methylation values in brain tightly regulate
Figure 3. Phenotype analysis of Hoxb7a-overexpression in zebrafish embryos. A: Phenotype analysis at 72 hpf of Hoxb7a mRNA injected zebrafish
resulted in significant hypopigmentation and malformation in 66% of the injected zebrafish. These embryos had shorter anterior/posterior axes as well
as crooked or bent tails. B: Phenotype analysis after pax2a at 24 hpf resulted in about 63% embryos with a mild or severe affected phenotype after
Hoxb7a overexpression compared to 13% in injected controls. C: Pax2a staining after microinjection of different concentrations of mRNA. From left to
right severe, mild affected and wild type (WT) embryos at 24 hpf. WT zebrafish show expression in the hindbrain, hindbrain-midbrain boundary, neural
tube, mesoderm, optic stalk, otic vesicle, and pronephric duct. Microinjection 62.5 mMmRNA, 125 mMmRNA and 250 mMmRNA resulted in respectively
48%, 71% and 61% malformed zebrafish. There was no correlation between mRNA dosage and severity of malformation.
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295 higher and stable gene expression levels compared to the higher
methylation levels in blood that are associated with a variable
HOXB7 gene expression. These data would suggest that HOXB7
hypomethylation is associated with higher gene expression. A
limitation of our study was the lack of HOXB7 gene expression
300 studies using leukocyte RNA from MMC cases and unrelated
healthy controls as RNA samples were not collected. Additional
studies are needed to correlate the methylation levels of the
HOXB7 gene body CpGs with HOXB7 gene or protein expres-
sion values. Furthermore, it would be interesting to compare our
305 findings in leukocytes with those from neural tissue.
Conclusion
This is the first study that uses genome-wide DNA methyla-
tion data for the locus-specific analysis of the different HOX
genes in patients with NTDs. We found evidence that HOXB7
310 hypomethylation is a potential risk factor for MMC but also that
the underlying methylation defect is present in both affected and
non-affected offspring. This could confirm the hypothesis that
children born from mothers with folic acid resistance and a dis-
turbed methylation cycle, can present with alterations in DNA
315 methylation with high risk for abnormal embryonic develop-
ment. Investigating the complex etiology of NTDs requires con-
sideration of more DNA methylation studies; therefore, genome-
wide DNA methylation analysis without focusing on candidate
pathways could reveal more epigenomic changes associated with
320 NTDs. The challenge ahead is to determine which DNA regions
are more sensitive to methylation changes during embryogenesis
and lead to NTDs.
Materials and Methods
Ethics statement
325 Written informed consent to collect blood samples for (epi)
genetic studies was obtained from all participants and/or their
legal representatives. This study was approved by the Medical
Ethics Committee of the University of Leuven (study ML9193).
Description of MMC patients, related healthy siblings and
330 unrelated healthy controls
A total of 85 MMC patients and 12 healthy related siblings
enrolled in this study are followed at the pediatric neurology
department of the University Hospital Leuven (all <18 y old).
Detailed clinical and general characteristics for all these subjects
335 are reported in Table 1. As sensory and motor functions at and
below the level of the spinal cord defect are impaired, paralysis,
bowel, and bladder dysfunction is present in most of the patients.
Folic acid supplementation was recommended, but red blood cell
folate was not measured during pregnancy. Table 1 also indicates
340 which MMC patients were included in the 450K array and/or
the Sequenom validation study. In addition, we have recruited
30 age- and gender-matched non-related healthy control subjects
with no family history of NTDs (15 males and 15 females).
Genome-wide DNA methylation analysis using the Illumina
345450K BeadChip array
Genome-wide DNA methylation analysis was assessed using
Illumina Infinium HumanMethylation450 BeadChip (Illumina,
Inc., California, USA) that provides a genome-wide coverage of
CpG sites (99% of RefSeq genes, covering the promoter region,
35050UTR, first exon, gene body and 30UTR; Figure S1A). 32 Bisul-
fite conversion of leukocyte DNA (1 mg) was performed using the
EZ DNA methylation kit (Zymo Research, Irvine CA, USA).
Control nested PCR reactions were done on both unconverted
and converted DNA to verify DNA conversion. Arrays were proc-
355essed according to the manufacturer’s protocol. Samples were ran-
domly distributed to control for batch effects. Before analyzing
the data, possible sources of technical bias were excluded. Probes
were excluded from further analysis if >95% of samples had a
detection value>0.01. 33 The software GenomeStudio (Illumina)
360was used to convert on-chip fluorescent methylation values into
numerical values (b-value). Methylation, described as a b-value, is
a continuous variable ranging between 0 (no methylation) and 1
(full methylation) for each CpG site. From this genome-wide
analysis, we extracted the methylation levels for the different
365CpGs that cover all regions within theHOX clusters (for overview
see Table S1). We discarded the following probes (608 in total): i)
probes with absent signals in one or more of the DNA samples
analyzed; ii) non-CpG probes; iii) probes containing SNPs; and
iv) leukocyte-specific probes. 33 The signal processing was con-
370ducted using the Illumina Methylation Analyzer (IMA) package
implicated in the open source statistical environment R. 34 Two
filters were applied to identify differentially methylated CpGs
between MMC patients and controls: i) absolute b-value differ-
ence > 0.05 and ii) P-value < 0.05, as calculated with the Wil-
375coxon rank-sum test.
Methylation of CpGs within the HOXB7 gene body using
the Sequenom EpiTYPER
Leukocyte DNA (1 mg) was subjected to bisulfite treatment
using the MethylDetectorTM bisulfite modification kit (Active
380Motif, Carlsbad CA, USA) as we described. 35,36 The Seque-
nom MassARRAY (Sequenom, San Diego, CA, USA) was used
for quantitative DNA methylation analysis of the CpG island
within the HOXB7 gene body using conditions described. 35
Long cycling incubation was applied to further optimize the
385conversion reaction. 37 Primers were designed using the Seque-
nom EpiDesigner BETA software (www.epidesigner.com), tak-
ing into account amplicon coverage, number of CpGs,
fragment size and number of nucleotide repeats in the primer
sequence. The primers were: 50-aggaagagagGTGTTGGGAT-
390TATAGGTTTGAGTTT-30 and 50-cagtaatacgactcactataggga-
gaaggctACTAAACTTCTCTTCCTCTCCCTTTC-30. This
395 bp long amplicon covers 26 CpGs but the EpiTYPER anal-
ysis only detected 10 separate analytical units that comprise sin-
gle, duplicate or triplicate CpGs as shown in Figure 1A. The
395Illumina probe cg07547765 is similar as CpG6. The 2 other
Illumina probes cg11041817 and cg22622477 are located
within the studied CpG Sequenom amplicon but were not
detected by the EpiTYPER. PCR steps were performed in
8 Volume 0 Issue 0Epigenetics
triplicate for each DNA sample and a standard deviation
400 between replicates was mostly <10%. When triplicate measure-
ments had a SD > 10% or when only one of the triplicates was
available, data for that sample were excluded. The mean of 3
values was used for further analyses. The EpiTYPER analysis
method reports CpG methylation values as percentage. Statisti-
405 cal analyses to quantify DNA methylation differences were per-
formed using the Prism 6 software (GraphPad Software Inc.,
San Diego, CA, USA). A two-tailed T-test was used to assess
differences in mean DNA methylation levels between cohorts
for the overall HOXB7 amplicon considered as methylation
410 average and for each CpG unit within this amplicon separately.
MTHRF 677C>T genotyping
Leukocyte DNA from MMC patients, related healthy siblings
and unrelated healthy controls was screened for the presence of
the MTHFR 677C>T variant by PCR and restriction digestion
415 as described. 38
Functional in silico analysis of HOXB7 methylation
versus expression
A correlation between HOXB7 CpG promoter methylation
and gene expression was studied by data mining using the open
420 source database MENT (Methylation and Expression database of
Normal and Tumor tissues). 39 The database only included Illu-
mina 27K BeadChip CpG probes (cg09357097 and
cg06493080, as shown in Fig. 1A) that are located in the
HOXB7 promoter and not in the gene body.
425 Hoxb7a overexpression and depletion in zebrafish
Wild-type AB zebrafish strains were maintained according to
standard protocols. 40 Embryos were produced by natural mat-
ing and collected and fixed at different stages based on standard
morphological criteria. 41 To produce Hoxb7a mRNA, the full
430 coding Hoxb7a transcript (NM_001115091.2) was PCR ampli-
fied and cloned in the pGEM T Easy vector (Promega, Madi-
son, WI, USA). Forward and reverse primers were 50-
ATGAGTTCATTGTATTATGCGA-30 and 50-GTAGTTTA-
TACATCTATATTAA-30. Next, capped and polyadenylated
435 Hoxb7a mRNAs were synthesized using mMESSAGE
mMACHINE High Yield Capped RNA Transcription Kit
and Poly(A) Tailing Kit (both from Ambion, Austin, TX, USA)
according to the manufacturer’s protocol. The synthesized
mRNA was diluted in phenol red to different concentrations as
440 indicated in the figure legends. Morpholino (MO) injection was
performed with a splice Hoxb7a-MO (50-AGCACCTGT-
GAAAAGCGCAGAATGA-30). This MO was designed against
Chr17: 46,685,144–46,685,550. Off-target effects were assessed
by injecting with a standard control MO against b-globin (50-
445CCTCTTACCTCAGTTACAATTTATA 30). MOs were
designed by Gene Tools, LLC (Philomath, OR, USA). All
injected embryos were life-screened at 24, 48, and 72 hours
post-fertilization (hpf) using a Zeiss Lumar V12 (Carl Zeiss
Microscopy, Thornwood, NY, USA) and images were captured
450with a Leica DFC310 FX digital color camera (Leica Microsys-
tems, Wetzlar, Germany). Overexpression and depletion experi-
ments were performed in duplicate. Ethical approval was
obtained for these studies.
Pax2a whole mount in situ hybridization
455Whole mount In Situ Hybridization (WISH) with a probe for
the paired box gene 2a (pax2a) was performed 24 hours after
injection of MOs or Hoxb7a mRNA. Pax2a cDNA obtained
from Dr. W. Driever (University of Freiburg, Germany) was
cloned in the pGEM-3zfC for the synthesis of a digoxigenin
460(DIG) labeled antisense RNA probe as described. 42 The Pax2a
probe was subsequently used to analyze the influence of Hoxb7a
overexpression and inhibition on spinal cord and notochord for-
mation using standard morphological criteria. 41 WISH experi-
ments were performed in duplicate. Embryos were screened
465using a Zeiss Lumar V12 (Carl Zeiss Microscopy, Thornwood,
NY, USA) and images were captured with a Leica DFC310 FX
digital color camera (Leica Microsystems, Wetzlar, Germany).
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